[PDF] Top 20 Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
Has 10000 "Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?" found on our website. Below are the top 20 most common "Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?".
Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
... The primary endpoint of this study was to evaluate patient outcomes (treatment-related toxicities and antitumor activity) of patients with NSCLC who enrolled in at least one phase I trial. Toxicity ... See full document
34
Afatinib treatment in advanced non-small cell lung cancer
... of advanced non-small cell lung cancer (NSCLC), prognosis for these patients remains ...poor. Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase ... See full document
11
The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials
... inhibitors, have helped control tumor growth effectively for patients harboring specific genetic ...of patients have limited benefits due to lack of driver mutation, especially for ... See full document
8
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
... that have been used as the basis for FDA ...recent trials of PD-1 inhibitors in NSCLC, and there is very limited data about the frequency of immune-related response phenomena such as pseudoprogression in ... See full document
10
Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials
... published phase III RCT regarding the OS benefit of anti-PD-1/anti-PD-L1 agents versus docetaxel in patients with progressive advanced ...summary, patients receiving these checkpoint inhibi- ... See full document
11
A Phase II Study of Erlotinib in Patients with Previously Treated Non Small Cell Lung Cancer
... in patients with pre- viously treated advanced NSCLC in the pivotal trial ...and Drug Administration in 2004 for the treatment of patients with advanced NSCLC who have ... See full document
11
Clinical development of nintedanib for advanced non-small-cell lung cancer
... white patients with advanced nonsquamous NSCLC after the failure of first-line ...for patients treated with nintedanib plus pemetrexed compared with placebo plus pemetrexed (median PFS of ... See full document
6
<p>Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study</p>
... a Phase III clinical trial (ALTER0303), anlotinib prolonged the median progression-free survival (PFS) by 4 months and the median overall survival (mOS) by ...in patients with advanced NSCLC ... See full document
9
Developments in the Management of Advanced Non Small Cell Lung Cancer
... in patients with advanced non small cell lung cancer (NSCLC) remains to the day highly ...with small molecule tyrosine kinase inhibitors, the role of crizotinib and ... See full document
6
Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.
... phase I unit may be considered, to allow patients to enter trials before the natural course of the disease reaches this in fl exion ...ABC patients who did eventually enter a ... See full document
7
Safety and Efficacy of Racotumomab Alum Vaccine as Second Line Therapy for Advanced Non Small Cell Lung Cancer
... extensive clinical research in non-small cell lung cancer (NSCLC), overall survival is still ...anti-idiotypic cancer vaccine that targets NeuGcGM3 tumor asso- ciated ... See full document
8
Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
... in patients with wild- type EGFR and lung cancer has been ...unselected patients with lung cancer,[9] though there is a general consensus that patients with sensitive EGFR ... See full document
13
Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis
... analyzing patients with nonsquamous histology ...for advanced nonsquamous NSCLC patients remains ...for advanced nonsquamous NSCLC patients. We thus perform this study of ... See full document
6
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions
... possible drug- related problems” [1]. The correct Adverse drug reaction definition (ADRs) is : reaction noxious and unintended, to medicinal products used at doses normally used in man for the prophylaxis, ... See full document
6
Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design
... to patients at varying distances from the hospital, particularly in Sweden – this study aims to determine the feasibility both for patients in urban set- tings and those who live many miles from ...that ... See full document
12
EFFICACY AND SAFETY OF SUPPLEMENTS IN CANCER PATIENTS: A 10-YEAR REVIEW AND UPDATES
... neck cancer patients with good ...or clinical outcome following oesophagogastric cancer ...surgical patients, without reducing the risk of postoperative ... See full document
8
Survival of patients treated with antibiotics and immunotherapy for cancer: A systematic review and meta-analysis
... Our meta-analysis has some limitations. First, this is a meta-analysis of retrospective series with heterogeneous populations and obvious diversity in tumor stages/types and patient characteristics. Also, AB type and ... See full document
17
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
... promising clinical trial results in AML patients regardless of FLT3 status achieved by other multi- targeted inhibitors like SU11248 and PTK787/ZK 222584 ...AML cell line, HL60 in a xenograft ...an ... See full document
13
Diagnostic and Prognostic Value of Serum Tissue Polypeptide Antigen in Advanced Lung Cancer
... The present study showed a trend towards significant correlation between high TPA and progressive disease although not reaching statistical significance. Again the present study did not show significant correlation with ... See full document
7
The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small-cell lung cancer patients treated with EGFR TKI
... of patients with high level of pretreatment MLR ( ≥ ...in patients with low level of MRL was ...significant. We checked this with the proportional hazards assumption tests and confirmed that MLR is ... See full document
8
Related subjects